Announcements Trials

Browse Landscape

Phase

Phase 3 4 Phase 4 3 Phase NA 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vomiting 1 Pruritus 1 Nausea 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Breast Neoplasms 1

Interventions

Paclitaxel 81 Trastuzumab 76 Fulvestrant 55 Cyclophosphamide 49 Capecitabine 42 Lapatinib 40 pembrolizumab 39 Docetaxel 38 palbociclib 36 Carboplatin 33 Letrozole 28 olaparib 23 Doxorubicin 23 Gemcitabine 21 Taxes 20 Everolimus 20 ribociclib 19 abemaciclib 19 Ado-Trastuzumab Emtansine 18 pertuzumab 17 Radiotherapy 17 Magnetic Resonance Spectroscopy 17 Bevacizumab 16 130-nm albumin-bound paclitaxel 16 exemestane 15 Vinorelbine 15 Cisplatin 15 veliparib 14 Biopsy 14 Alpelisib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Breast Neoplasms × Aprepitant × Clear all

NCT00719173 2024-11-04

NRR

UNC Lineberger Comprehensive Cancer Center

Phase 1 Completed

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡